Click here for more information about how we are dealing with COVID-19 and what you should do for your visit.
Skip to main content


Parkinson's Disease Clinical Trial

Parkinson's disease afflicts over one million people in the United States causing a decline in motor skills and cognition due to the destruction of dopamine producing neurons in the brain. Current research targets dopamine receptors in the brain.
Mar 8th, 2021

Alzheimer's Phase 2 Clinical Trial Success

Neurology Diagnostics is proud to announce our participation and enrollment of patients in the Eli Lilly Alzheimer's disease study recently reported in the New York Times.
Jan 20th, 2021

Neurology Diagnostics Digest - September 28, 2023

Neurology Diagnostics Newsletter Summary [date] Accepting new patients, streamlined referrals, FDA-approved Alzheimer's drug Leqembi, and upcoming clinical trials for Alzheimer's, CTE, and Parkinson's. Join us in advancing neurological care.
Sep 28th, 2023